Guardant Health's 3.43% Drop Amid 89% Volume Surge to 397th Market Activity Rank

On September 24, 2025, Guardant Health (GH) closed down 3.43% despite a surge in trading activity. The stock recorded a volume of $250 million, marking an 89.05% increase from the previous day's volume and ranking 397th in market activity among U.S.-listed equities. The divergence between elevated liquidity and price depreciation suggests short-term market dynamics may be influencing investor sentiment.

Recent developments highlight ongoing challenges in the liquid biopsy sector. Guardant's latest earnings report indicated mixed performance in key markets, with underwhelming adoption rates in its companion diagnostic products. Analysts have noted persistent skepticism about the company's ability to differentiate its multi-cancer early detection offerings in a rapidly evolving competitive landscape. These structural concerns appear to be amplifying near-term volatility despite the surge in trading interest.

To build an accurate back-test we need to pin down a few practical details: 1. Universe of stocks • Should the ranking cover every U.S.-listed common stock, or a specific universe (e.g., Russell 3000, S&P 500 constituents, NYSE-listed issues only, etc.)? 2. Trading signal timing • Do we buy at the day’s close (using that day’s volume rank) and exit at the next day’s close, or another open/close combination? 3. Weighting scheme • Equal-weighted across the 500 names, or volume-weighted / market-cap-weighted? 4. Transaction costs & slippage (if any) 5. Benchmark (optional) you’d like to compare against 6. Any risk controls (max drawdown, stop-loss, etc.) to overlay? Once these items are set I can pull the daily volume data, generate the rebalancing signals, and run the back-test from 2022-01-03 through today. Let me know your preferences, or feel free to accept the common defaults below: • Universe: all primary-listed U.S. common stocks (NYSE + Nasdaq, excluding ETFs & ADRs) • Signal timing: buy at today’s close, sell at tomorrow’s close • Weighting: equal-weighted across the selected 500 stocks • Transaction costs: none • No additional risk controls